Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding - PubMed (original) (raw)
Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding
N Yamaguchi et al. EMBO J. 1999.
Abstract
Endostatin, produced as recombinant protein in human 293-EBNA cells, inhibits the migration of human umbilical vein endothelial cells (HUVECs) in response to vascular endothelial growth factor (VEGF) in a dose-dependent manner and prevents the subcutaneous growth of human renal cell carcinomas in nude mice at concentrations and in doses that are from 1000- to 100 000-fold lower than those previously reported. The inhibition of migration is not affected by mutations which eliminate Zn or heparin binding and inhibition of tumor growth does not depend on Zn binding. The results of the migration assays suggest that endostatin causes a block at one or more steps in VEGF-induced migration, while VEGF in turn can cause a block of the inhibition by endostatin of VEGF-induced migration of HUVECs.
Similar articles
- Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR/Flk-1.
Kim YM, Hwang S, Kim YM, Pyun BJ, Kim TY, Lee ST, Gho YS, Kwon YG. Kim YM, et al. J Biol Chem. 2002 Aug 2;277(31):27872-9. doi: 10.1074/jbc.M202771200. Epub 2002 May 23. J Biol Chem. 2002. PMID: 12029087 - Endostatins derived from collagens XV and XVIII differ in structural and binding properties, tissue distribution and anti-angiogenic activity.
Sasaki T, Larsson H, Tisi D, Claesson-Welsh L, Hohenester E, Timpl R. Sasaki T, et al. J Mol Biol. 2000 Sep 1;301(5):1179-90. doi: 10.1006/jmbi.2000.3996. J Mol Biol. 2000. PMID: 10966814 - Dephosphorylation of endothelial nitric oxide synthase contributes to the anti-angiogenic effects of endostatin.
Urbich C, Reissner A, Chavakis E, Dernbach E, Haendeler J, Fleming I, Zeiher AM, Kaszkin M, Dimmeler S. Urbich C, et al. FASEB J. 2002 May;16(7):706-8. doi: 10.1096/fj.01-0637fje. Epub 2002 Mar 12. FASEB J. 2002. PMID: 11978735 - Anticancer drug targets: approaching angiogenesis.
Keshet E, Ben-Sasson SA. Keshet E, et al. J Clin Invest. 1999 Dec;104(11):1497-501. doi: 10.1172/JCI8849. J Clin Invest. 1999. PMID: 10587512 Free PMC article. Review. No abstract available. - Angiostatic proteins and peptides.
Bouma-ter Steege JC, Mayo KH, Griffioen AW. Bouma-ter Steege JC, et al. Crit Rev Eukaryot Gene Expr. 2001;11(4):319-34. Crit Rev Eukaryot Gene Expr. 2001. PMID: 12067070 Review.
Cited by
- Nano to micro delivery systems: targeting angiogenesis in brain tumors.
Gilert A, Machluf M. Gilert A, et al. J Angiogenes Res. 2010 Oct 8;2(1):20. doi: 10.1186/2040-2384-2-20. J Angiogenes Res. 2010. PMID: 20932320 Free PMC article. - Lack of collagen XVIII/endostatin results in eye abnormalities.
Fukai N, Eklund L, Marneros AG, Oh SP, Keene DR, Tamarkin L, Niemelä M, Ilves M, Li E, Pihlajaniemi T, Olsen BR. Fukai N, et al. EMBO J. 2002 Apr 2;21(7):1535-44. doi: 10.1093/emboj/21.7.1535. EMBO J. 2002. PMID: 11927538 Free PMC article. - Endogenous Antiangiogenic Factors in Chronic Kidney Disease: Potential Biomarkers of Progression.
Tanabe K, Sato Y, Wada J. Tanabe K, et al. Int J Mol Sci. 2018 Jun 24;19(7):1859. doi: 10.3390/ijms19071859. Int J Mol Sci. 2018. PMID: 29937525 Free PMC article. Review. - The effects of cetuximab alone and in combination with endostatin on vascular endothelial growth factor and interleukin-8 expression in human lung adenocarcinoma cells.
Yu YF, Chen ZW, Li ZM, Li ZH, Lu S. Yu YF, et al. Curr Ther Res Clin Exp. 2009 Apr;70(2):116-28. doi: 10.1016/j.curtheres.2009.03.001. Curr Ther Res Clin Exp. 2009. PMID: 24683223 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources